Status:
COMPLETED
SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy
Lead Sponsor:
Chimei Medical Center
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
A glycyrrhizin-containing product, Stronger Neo-Minophagen C TM (SNMC; Minophagen Pharmaceutical Co.Ltd.,Tokyo,Japan),is widely used in Japan for suppression of hepatitis activity and for prevention o...
Detailed Description
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the most common primary liver cancer. There are a variety of therapies for treatment of HCC; among them, transarterial c...
Eligibility Criteria
Inclusion
- Intermediate-stage HCC according to the Barcelona Clinic Liver Cancer (BCLC) staging system, either treatment naïve or experienced.
- Child's score belong to A or B(7)
- Total bilirubin level \<2 and Prothrombin time prolong \<3"
Exclusion
- Had history of liver decompensation (ascites, encephalopathy, jaundice and varices bleeding) before this TACE
- has allergic history of SNMC
- consensus form cannot be available
- hypokalemia (\<3.5 mmol/L)
Key Trial Info
Start Date :
April 12 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04015245
Start Date
April 12 2018
End Date
May 28 2019
Last Update
July 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ChiMei Medical Center
Tainan, Taiwan, 71004